Aripiprazole LAI two‐injection start in a 16 year‐old adolescent with schizophrenia

Salvi, Virginio; Appignanesi, Cristina; Marpepa, Brodinela; Orsolini, Laura; Volpe, Umberto

doi:10.1002/npr2.12240

Cited by 10 publications

(5 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The included articles comprised one open-label trial [ 38 ], one observational prospective study [ 39 ], four retrospective chart review studies [ 28 , 40 – 42 ], four single case reports [ 43 – 46 ], and three case series (of 2, 3, and 6 patients with SSD) [ 47 – 49 ]. One study included a patient age range of 13–18 years, but the mean age was < 18 years (15.9 ± 3.3) [ 38 ].…”

Section: Resultsmentioning

confidence: 99%

“…Lastly, the case of an adolescent with schizophrenia starting LAI aripiprazole with two injections was reported [ 46 ]. A 16-year-old inpatient male experienced clinical improvement of the psychotic symptoms with aripiprazole 30 mg/day and clozapine 100 mg/day.…”

Section: Resultsmentioning

confidence: 99%

“…LAIAs were linked to an improvement of clinical symptoms in most of the studies included, both with first-generation [ 40 , 49 ] and second-generation drugs [ 28 , 39 – 46 ] or with a combination of both [ 48 ]. Better functional outcome, and a smaller number of hospitalizations than with adolescents on oral AP were also reported after 12-month follow-up [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review

et al. 2023

View full text Add to dashboard Cite

Background Long-acting injectable antipsychotics (LAIAs) are an efficacious and well-tolerated treatment in adults with schizophrenia spectrum disorders (SSD). However, there is less evidence for their use in children and adolescents. Objectives The aim of this systematic review was to summarize findings regarding the effectiveness and side effects of LAIA in children and adolescents with SSD. Methods Four databases (Web of Science, PubMed, MEDES, and Dialnet) were systematically searched for articles published between inception and 12 March, 2022, with the following inclusion criteria: (1) original articles or case reports; (2) providing data on efficacy/effectiveness or safety/tolerability of LAIA treatment in children and adolescents diagnosed with SSD (schizophrenia, schizoaffective disorder, schizophreniform disorder, non-affective psychotic disorder); (3) mean age of samples ≤ 18 years; and (4) written in English or Spanish. Exclusion criteria were review articles, clinical guides, expert consensus as well as posters or oral communication in conferences. The risk of bias was assessed using the ROBIS tool. Results From 847 articles found, 13 met the inclusion criteria. These included seven single case reports or case series, four retrospective chart reviews, a 24-week open-label trial, and one observational prospective study, covering a total of 119 adolescents (aged 12–17 years) with SSD. Almost all the articles described data on second-generation LAIA (53 patients on risperidone [once every other week], 33 on paliperidone palmitate [once monthly], 10 on aripiprazole [once monthly], and two on olanzapine pamoate [once monthly]). Twenty-one patients were reported to be only on first-generation LAIAs. Non-adherence was the main reason for starting an LAIA. In all of the studies, the use of LAIAs was associated with improvement in the patients’ symptoms. Conclusions There are few studies assessing the use of LAIAs in adolescents with SSD. Overall, these treatments have suggested good effectiveness and acceptable safety and tolerability. However, we found no studies examining their use in children aged < 12 years. The problems and benefits linked to this type of antipsychotic formulation in the child and adolescent population require further study, ideally with prospective, controlled designs. Supplementary Information The online version contains supplementary material available at 10.1007/s40272-023-00558-x.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…The AOM400-TIS was proposed based on a simulation pointing to a profile similar to that of the AOM400 1 injection start that involves 1 injection and oral supplementation for 14 days, suggesting similar stable plasma levels of aripiprazole and no incremental safety risk 16 . After the approval of AOM400-TIS, one study analyzed the efficacy and safety of this alternative regimen, obtaining favorable results, but it was a single case study in an adolescent for whom the LAI formulation was off-label 36 . Therefore, to our knowledge, the SaTISfy study is describing for the first time the experience of psychiatrists with AOM400-TIS in a real-world setting.…”

Section: Discussionmentioning

confidence: 99%

“… 16 After the approval of AOM400-TIS, one study analyzed the efficacy and safety of this alternative regimen, obtaining favorable results, but it was a single case study in an adolescent for whom the LAI formulation was off-label. 36 Therefore, to our knowledge, the SaTISfy study is describing for the first time the experience of psychiatrists with AOM400-TIS in a real-world setting.…”

Section: Discussionmentioning

confidence: 99%

Clinical Experience on the Use of a Single-day, Two-injection Start Initiation Regimen of Aripiprazole Once Monthly in Patients With Schizophrenia in Spain: SaTISfy Study

BIOQUE,

MORENO,

GÓMEZ-LUS

et al. 2024

Journal of Psychiatric Practice

View full text Add to dashboard Cite

Objective: The two-injection start (TIS) initiation regimen was recently approved for aripiprazole once monthly 400 mg (AOM400), with potential benefits in adherence. The SaTISfy study described in this article analyzed Spanish psychiatrists’ perspectives on hospitalization lengths of stay, schizophrenia management, and the use of AOM400-TIS. Methods: The authors describe an ecological study of aggregated data collected using a 41-question survey. Fifty psychiatrists were asked to provide their perceptions of their patients with schizophrenia and treatment with AOM400. Results: The psychiatrists reported that lack of treatment adherence was the main reason for hospitalization for 58.3% of their patients diagnosed with schizophrenia. Aripiprazole, in any formulation, was the most commonly prescribed therapeutic option, being prescribed for a mean (SD) of 2.5 (0.9) out of 5 patients, while 98% of psychiatrists chose AOM400-TIS for patients who failed to adhere to previous treatments. Patients with schizophrenia, regardless of their treatment, were hospitalized for an average of 17.7 (3.93) days versus patients with schizophrenia treated with AOM400-TIS, who were hospitalized for an average of 14.2 (4.18) days, a reduction of 3.5 (3.86) days. Patients treated with AOM400-TIS showed a reduction of 5 (4.18) days compared with the mean national duration of hospitalization for acute patients in psychiatry units in Spain (19.18 d). The surveyed psychiatrists reported that AOM400-TIS improved safety and tolerability. Most of the psychiatrists were satisfied with the administration and results of AOM400-TIS. Most of the psychiatrists (90%) also reported that fewer health care resources were consumed with AOM400-TIS, mainly due to a reduction in hospitalization days and in the use of concomitant medications. Conclusions: AOM400-TIS was considered to have a positive impact on the duration of hospitalization and thus on the use of health care resources. There was a positive perception of adherence, safety, and tolerability with the use of AOM400-TIS in patients with schizophrenia.

show abstract

Aripiprazole LAI two‐injection start in a 16 year‐old adolescent with schizophrenia

Salvi

Appignanesi

Marpepa

et al. 2022

Neuropsychopharm Rep

View full text Add to dashboard Cite

Background: Aripiprazole long-acting injection (LAI) is approved for the treatment of schizophrenia in adults. Recently, Europe and Canada approved the use of the twoinjection start regimen: two separate injections of 400-mg long-acting aripiprazole along with a single 20-mg dose of oral aripiprazole. Aripiprazole showed efficacy in the treatment of adolescents with acute schizophrenia in several controlled trials, leading to its approval for 13-to 17-year-old adolescents with schizophrenia by the EMA. However, the LAI formulation still remains off-label in adolescents. Case presentation:The patient was admitted to the General Psychiatry inpatient unit with a Positive and Negative Syndrome Scale (PANSS) total score of 136 and the Clinical Global Impression (CGI) score of 7. Aripiprazole was started and up-titrated to 30 mg/d. After 3 weeks, the positive symptoms were significantly reduced; however, he still showed prominent negative symptoms. Clozapine 100 mg/d was added, and in the following 2 weeks, the patient appeared slightly more communicative and generally more aware of himself and the others. The PANSS total score decreased to 81. Due to poor insight, the patient was at-risk not to take medications upon returning home; therefore, aripiprazole LAI was proposed. Since he urged to be discharged from the hospital, we opted for the two-injection start. The medication was optimally tolerated, with no evidence of akathisia or other side effects. One month later, global functioning and illness insight improved; Positive and Negative Syndrome Scale score was 43 and CGI score 2.Conclusions: Aripiprazole LAI showed good efficacy and tolerability in an adolescent with schizophrenia. The two-injection start regimen was a safe and effective option.

show abstract

Aripiprazole LAI two‐injection start in a 16 year‐old adolescent with schizophrenia

Cited by 10 publications

References 14 publications

What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review

What Role for Long-Acting Injectable Antipsychotics in Managing Schizophrenia Spectrum Disorders in Children and Adolescents? A Systematic Review

Clinical Experience on the Use of a Single-day, Two-injection Start Initiation Regimen of Aripiprazole Once Monthly in Patients With Schizophrenia in Spain: SaTISfy Study

Aripiprazole LAI two‐injection start in a 16 year‐old adolescent with schizophrenia

Contact Info

Product

Resources

About